Design to market approval

Product Development

Services & Technology Consulting

Products with need to the market and with a combination of strong and science and deep operational excellence, Theertha aims to direct its potential to transform therapeutic strategies for disease treatment bringing a regenerated and rejenuvated global healthy living.


Pipeline Product

Microbial Product 1

Insulin analog (Modified Peptide) for diabetes, controlling hyperglycemia produced with high titer and recovery using our microbial platform technology

POC by Q2 2021 Phase I ready by Q4 2021

Microbial Product 2

Thrombolytic Agent for acute myocardial Infarction.

POC  by  Q2 2021 Phase I ready by  Q4 2021

Microbial Product 3

Modified peptide for diabetes for controlling Obesity and Hyperglycemia.

PCT Completion Q4 2020 Phase I ready by Q3 2021

Microbial Product 4

Antibody for Inflammatory disease. Using best CHO GS(-/-) cell line and proprietary platform technologies produced with high titre and highly similar product isoforms.

POC  by  Q2 2021 Phase I ready by  Q4 2021


The Product development is considered for global market approval.  A collaborative approach helps in bringing the product to the market at the earliest for a greater benefit to organization and patients.

Contract Services

Open for development of the product of partners choice. We take care of the complete life cycle management of Biosimilars and novel products.

Call Us



Plot No#132(B), Bommasandra Jigani Link Road, Industrial Area, Anekal Taluk, Bangalore, India- 560 105

error: checked